Myovant Sciences Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYOVANT SCIENCES, and when can generic versions of MYOVANT SCIENCES drugs launch?
MYOVANT SCIENCES has two approved drugs.
There are eight US patents protecting MYOVANT SCIENCES drugs.
There are eighty-four patent family members on MYOVANT SCIENCES drugs in thirty countries and twenty-two supplementary protection certificates in thirteen countries.
Summary for Myovant Sciences
| International Patents: | 84 |
| US Patents: | 8 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Myovant Sciences
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myovant Sciences | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | RX | Yes | Yes | 11,033,551 | See Plans and Pricing | See Plans and Pricing | ||||
| Myovant Sciences | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 7,300,935 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Myovant Sciences | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Myovant Sciences | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 10,449,191 | See Plans and Pricing | See Plans and Pricing | ||||
| Myovant Sciences | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 8,058,280 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Myovant Sciences Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3518932 | See Plans and Pricing |
| China | 101153042 | See Plans and Pricing |
| Israel | 265700 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2018060501 | See Plans and Pricing |
| Denmark | 1591446 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Myovant Sciences Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0334429 | 97C0002 | Belgium | See Plans and Pricing | PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305 |
| 1453521 | C201630040 | Spain | See Plans and Pricing | PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211 |
| 0398460 | 12/2004 | Austria | See Plans and Pricing | PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211 |
| 1453521 | 300814 | Netherlands | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| 1453521 | 15C0050 | France | See Plans and Pricing | PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
